Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units: a multi-institution database study
Clicks: 97
ID: 269578
2021
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
28.8
/100
97 views
4 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #103 of 131 articles by views in annals of intensive care
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 131 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Levosimendan did not increase short- or long-term mortality rates in critical patients with acute heart failure and reduced ejection fraction compared to dobutamine, regardless of their renal function. An eGFR less than 30 mL/min/1.73 m2 was not necessarily considered a contraindication f …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (42 words).
Try re-searching for a better abstract.
| Reference Key |
cc2021annalslevosimendan
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Chan CC;Lee KT;Ho WJ;Chan YH;Chu PH;; |
| Journal | annals of intensive care |
| Year | 2021 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.